Ceftaroline: a cephalosporin with expanded Gram-positive activity.

Abstract

Infections caused by resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are now posing a major health risk for patients in hospital and community settings. There is a need to evaluate new antibiotics that would offer reliable clinical efficacy combined with a favorable safety profile for the treatment of such infections. Ceftaroline is a new member of the cephalosporin class of antibiotics with expanded activity against Gram-positive pathogens such as MRSA, vancomycin-intermediate S. aureus, vancomycin-resistant S. aureus and multidrug-resistant Streptococcus pneumoniae, while retaining good activity against common Gram-negative organisms. Phase II and III studies have shown ceftaroline to be an effective and well-tolerated treatment for complicated skin and skin-structure infections compared with standard therapy. Trials are ongoing in the treatment of community-acquired pneumonia.

• Authors: Zeina A Kanafani, G Ralph Corey
• Journal: Future microbiology (Future Microbiol) Vol. 4 Issue 1 Pg. 25-33 (Feb 2009) ISSN: 1746-0921 [Electronic] England
• PMID: 19207097 (Publication Type: Journal Article, Review)

Chemical References

• Cephalosporins
• T 91825

Topics

• Adult
• Animals
• Cephalosporins (administration & dosage, adverse effects, pharmacology, therapeutic use)
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Gram-Positive Bacterial Infections (drug therapy, microbiology)
• Gram-Positive Cocci (drug effects)
• Humans
• Mice
• Skin Diseases, Bacterial (drug therapy, microbiology)
• Treatment Outcome